Condition: Vulvo Vaginal Atrophy (VVA) · Sponsor: Azure Biotech Inc.
Study Objectives: Primary: • To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: • To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium
This description comes directly from the study's public registry record.
Howard Levy, MD PhD · (848) 992-5888 · hlevy@hlevyconsulting.com
Susan L Levinson, PhD · 973-4762430 · slevinson@azurebiotech.com
Always discuss trial participation with your own doctor first.
| Nucleus Network | Saint Paul, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06197568